Bora Pharmaceuticals Co., Ltd. (TPE:6472)
Taiwan · Delayed Price · Currency is TWD 455.00
-6.00 (-1.30%)
At close: Mar 26, 2026
Bora Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 19,014 | 17,427 | 14,200 | 10,494 | 4,900 | |
Revenue Growth (YoY) | 9.11% | 22.72% | 35.31% | 114.18% | 172.28% |
Cost of Revenue | 11,161 | 9,636 | 7,209 | 7,582 | 3,228 |
Gross Profit | 7,853 | 7,791 | 6,991 | 2,913 | 1,672 |
Selling, General & Admin | 3,886 | 3,444 | 1,444 | 861.52 | 584.52 |
Research & Development | 672.21 | 638.88 | 298.16 | 129.08 | 41.27 |
Other Operating Expenses | 1.75 | - | - | - | - |
Operating Expenses | 4,559 | 4,083 | 1,742 | 990.6 | 625.79 |
Operating Income | 3,294 | 3,708 | 5,249 | 1,922 | 1,046 |
Interest Expense | -484.62 | -479.72 | -171.24 | -108.73 | -53.62 |
Interest & Investment Income | 29.35 | 91.42 | 62.95 | 11.36 | 0.22 |
Earnings From Equity Investments | -452.96 | -0.04 | - | - | - |
Currency Exchange Gain (Loss) | -125.88 | 163.52 | -67.51 | 47.92 | -14.41 |
Other Non Operating Income (Expenses) | 53.83 | 65.84 | 39.98 | 17.41 | 48.02 |
EBT Excluding Unusual Items | 2,313 | 3,549 | 5,113 | 1,890 | 1,026 |
Gain (Loss) on Sale of Investments | 2,965 | 11.56 | -1,044 | -47.79 | - |
Gain (Loss) on Sale of Assets | - | - | -5 | -2.36 | -2.24 |
Other Unusual Items | - | 1,663 | - | - | - |
Pretax Income | 5,278 | 5,223 | 4,064 | 1,840 | 1,024 |
Income Tax Expense | 829.85 | 1,006 | 992.23 | 438.48 | 274.23 |
Earnings From Continuing Operations | 4,448 | 4,218 | 3,072 | 1,402 | 749.74 |
Earnings From Discontinued Operations | -1,402 | -263.65 | - | - | - |
Net Income to Company | 3,046 | 3,954 | 3,072 | 1,402 | 749.74 |
Minority Interest in Earnings | -64.73 | -101.39 | -41.78 | -9.61 | - |
Net Income | 2,981 | 3,853 | 3,030 | 1,392 | 749.74 |
Net Income to Common | 2,981 | 3,853 | 3,030 | 1,392 | 749.74 |
Net Income Growth | -22.61% | 27.14% | 117.70% | 85.65% | 29.62% |
Shares Outstanding (Basic) | 125 | 122 | 120 | 117 | 116 |
Shares Outstanding (Diluted) | 189 | 141 | 124 | 118 | 117 |
Shares Change (YoY) | 33.62% | 13.61% | 4.93% | 1.41% | 0.86% |
EPS (Basic) | 23.90 | 31.54 | 25.17 | 11.89 | 6.44 |
EPS (Diluted) | 15.81 | 27.29 | 24.50 | 11.78 | 6.42 |
EPS Growth | -42.08% | 11.42% | 107.94% | 83.40% | 28.53% |
Free Cash Flow | 3,575 | 451.92 | 4,316 | 1,815 | 1,073 |
Free Cash Flow Per Share | 18.95 | 3.20 | 34.74 | 15.33 | 9.19 |
Dividend Per Share | 10.000 | 14.000 | 10.002 | 5.133 | 2.041 |
Dividend Growth | -28.57% | 39.98% | 94.84% | 151.53% | 118.14% |
Gross Margin | 41.30% | 44.70% | 49.23% | 27.76% | 34.12% |
Operating Margin | 17.32% | 21.28% | 36.97% | 18.32% | 21.35% |
Profit Margin | 15.68% | 22.11% | 21.34% | 13.26% | 15.30% |
Free Cash Flow Margin | 18.80% | 2.59% | 30.39% | 17.30% | 21.90% |
EBITDA | 4,214 | 4,565 | 5,734 | 2,169 | 1,211 |
EBITDA Margin | 22.16% | 26.20% | 40.38% | 20.67% | 24.72% |
D&A For EBITDA | 920.39 | 857.49 | 485.11 | 246.69 | 165.27 |
EBIT | 3,294 | 3,708 | 5,249 | 1,922 | 1,046 |
EBIT Margin | 17.32% | 21.28% | 36.97% | 18.32% | 21.35% |
Effective Tax Rate | 15.72% | 19.25% | 24.41% | 23.83% | 26.78% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.